NCBiotech News

The National Cancer Institute and Eva Garland Consulting have teamed up to help small businesses apply for Phase I of the federally funded SBIR and STTR grant programs.

The newly published "2018: Evidence and Opportunity: Impact of Life Sciences in North Carolina," is a fascinating statistical tale of the state's transformation, and the Biotechnology Center's 35-year contribution to it.

NCBiotech's Biomanufacturing and Process Development Exchange Group of industry professionals gathered for a symposium and vendor show earlier in April to confront the challenges of making cell and gene therapies.

Research Triangle Park-based Panaceutics is ramping up its financing and manufacturing capabilities to bring personalized nutrition products to market in collaboration with Dutch-based Royal DSM.

Precise Bio, a Winston-Salem regenerative medicine startup, has developed a laser-based biological “printer” that can fabricate tissues and organs from living cells in three dimensions, just as they are structured in the body.

EG-GILERO, a Morrisville-based medical device manufacturer, plans to invest more than $4 million and create 60 jobs in Chatham County, adding more finished-device assembly to augment its design, development and manufacturing services.

RTP's NIRvana Sciences, developer of synthetic dyes used in staining cells for analysis by flow cytometry, is awarded a $3 Million SBIR grant from NIH.

Circassia Pharmaceuticals, a British company with U.S. headquarters in Morrisville, has received U.S. Food and Drug Administration approval of Duaklir Pressair, a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).

Three North Carolina life science innovators strongly recommend others follow their lead and seek out the many resources provided by NCBiotech.

Durham-based Hatteras Venture Partners has completed a first closing of $94 million on a new investment fund that it hopes will reach $200 million.

The Research Triangle region hosts a growing ag tech industry as it combines history and innovation, draws on both urban and rural resources, and thrives on partnerships among private companies, government and academic institutions.

Asklepios BioPharmaceutical, (AskBio), a Research Triangle Park platform company playing a key role in North Carolina’s global gene therapy leadership, got a $235 million vote of confidence today.

Durham-based Mycovia Pharmaceuticals, a developer of drugs in women’s health, has shown that its oral drug candidate VT-1598 is active against Candida auris, an emerging multi-drug resistant fungal pathogen that presents a serious global health threat.

Speakers at an NCBiotech forum say personalized medicine is finally here to stay. And, driven by recent advances in genomics and lower genetic testing and sequencing costs, it’s transforming healthcare as we know it.

FHI 360, a Durham-based international nonprofit human development organization, has launched a subsidiary called FHI Clinical as a full-service contract research organization to manage complex clinical research in resource-limited settings around the world.